Group 1 - The company has entered into subscription agreements with three subscribers to issue a total of 160 million shares at a subscription price of HKD 0.097 per share, raising a total of HKD 2.91 million, HKD 1.94 million, and HKD 10.67 million respectively [2] - The net proceeds from the subscription will be used to support the group's potential new business development in the trade, manufacturing, sales, and distribution of health products, equipment, and technology in China, as well as to expand into overseas health-related business opportunities [2] - The company plans to continue using internal cash resources to maintain and develop its existing pharmaceutical business, believing that factors such as an aging population, increasing chronic diseases, heightened health awareness, and technological advancements will sustain the demand for health and patient care products and solutions in the healthcare industry [2]
精优药业拟配发1.6亿股